Indeed, the role of lipid-lowering agents, particularly PCSK9, and Niemann-Pick C1-like 1 (NPC1L1) inhibitors, in cystic kidney disease remains understudied. This evidence concerns the gene NPC1L1 and cystic kidney disease.